RecruitingNot ApplicableNCT02784119

APCext : Effect of Temporary Porto-caval Shunt During Liver Transplantation on Function of Liver Graft From Extended Criteria Donor


Sponsor

Rennes University Hospital

Enrollment

214 participants

Start Date

Mar 28, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

The success of orthotopic liver transplantation (OLT) in treatment of liver malignancy and endstage liver disease has led to an increase in the gap between patients on waiting-lists and available liver grafts. In order to compensate for this scarcity, use of liver grafts harvested from extended criteria donors (ECD) has become more and more frequent. However, these ECD grafts are known to be associated with a higher rate of primary non function (PNF) or early allograft dysfunction (EAD) because of a greater vulnerability to ischemia-reperfusion injury (IRI). During OLT, the clamping of the portal vein induces blood congestion in the splanchnic territory leading to increased gut permeability, bacterial translocation and release of endotoxin and pro-inflammatory cytokines at revascularisation, which exacerbate IRI. Realisation of a temporary porto-caval shunt (TPCS) (i.e. end to side anastomosis between the portal vein and infrahepatic vena cava) during the anhepatic phase, avoids splanchnic congestion and could therefore decrease IRI and improve liver graft function. However, TPCS remains poorly used as no randomised trial succeeds to show its benefit on liver function due to lack of power.


Eligibility

Min Age: 18 Years

Inclusion Criteria19

  • Age ≥ 18 years old
  • Candidate of liver transplantation
  • With cirrhosis from any etiology
  • Model For End-Stage Liver Disease (MELD) score < 25
  • Transplanted with a liver graft harvested from an extended criteria donor defined as presence of at least one of the following criteria:
  • Donor age > 65 years old
  • Intensive care unit stay > 7 days
  • BMI > 30
  • Natremia > 155 mmol/L
  • Aspartate aminotransferase (ASAT) > 150 IU/mL
  • Alanine aminotransferase (ALAT) > 170 IU/mL
  • Occurrence of a cardiac arrest before graft harvesting
  • Proven biopsy macrosteathosis > 30%
  • Non-opposition from the patient
  • Fulminant hepatitis
  • Retransplantation
  • Combined organ transplantation (kidney, pancreas, heart, lung)
  • Non heart beating donor
  • Complete portal vein thrombosis on preoperative imaging finding

Exclusion Criteria3

  • Complete portal vein thrombosis found during procedure
  • Split liver graft
  • Realisation of a bilio-enteric anastomosis

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREtemporary porto-caval shunt

temporary porto-caval shunt


Locations(6)

CHU Bordeaux

Bordeaux, France

Hospices Civils Lyon

Lyon, France

CHU Nice

Nice, France

CHU Rennes

Rennes, France

CHU Toulouse

Toulouse, France

CHU Tours

Tours, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02784119


Related Trials